Panel B shows proportions of HCWs who tested SARS-CoV-2 antibodyCpositive and Cnegative based on work location. Among all HCWs, there were differences in seropositivi-ty by job function (= .001). for nurses and 20.9% for administrative staff. Compared to administrative staff, aORs (95% CIs) for seropositivity were 2.54 (1.64-3.94) for nurses; 2.51 (1.42-4.43) for nonclinical HCWs; between 1.70 and 1.83 for allied HCWs such as patient care technicians, social workers, registration clerks and therapists; and 0.80 (0.50-1.29) for physicians. Compared to office locations, aORs for the emergency department and inpatient units were 2.27 (1.53-3.37) and 1.48 (1.14-1.92), respectively. CONCLUSION One-third of hospital-based HCWs were seropositive for SARS-CoV-2 by the end of the first Kv3 modulator 3 wave in NYC. Seroprevalence differed by job function and work location, with the highest estimated risk for nurses and the emergency department, respectively. These findings support current nationwide policy prioritizing HCWs for receipt of newly authorized COVID-19 vaccines. SARS-CoV-2 has infected more than 141 million people worldwide and 31 million people in the United States as of April 20, 2021.1,2 The influx of hospital admissions and deaths has severely strained healthcare systems worldwide and placed healthcare workers (HCWs) at increased risk for acquiring COVID-19.3-5 Several studies have described the impact of COVID-19 on this heterogeneous group of HCWs. Shields et al reported a seroprevalence of 24.4% in HCWs at University Hospitals Birmingham (UK), with the highest rate, 34.5%, in housekeeping staff.6 Steensels et al reported a lower prevalence of 6.4% at a tertiary care center in Belgium, and showed no increased risk for HCWs when directly involved in clinical care.7 The authors attributed this to adequate use of personal protective equipment (PPE). Other studies have reported seroprevalences ranging from 1.6% to 18%.8-11 In the New York City (NYC) metro area, Jeremias et al reported a seroprevalence of 9.8% in HCWs and found no difference by job title or work location,12 whereas Moscola et al reported a seroprevalence of Kv3 modulator 3 13.7% and demonstrated a 3% increased risk for SHCB those working in service or maintenance.april 2020 in every but two of the research 13 Antibody testing were conducted between March and; between Apr 13 and June 23 tests in both of these research was performed, 2020, with one confirming a seroprevalence of 6%11 as well as the additional, 13.7%.13 NYC became the initial pandemic epicenter in america following untracked transmitting from ongoing circulation of SARS-CoV-2 in Europe.14 As a complete result, the COVID-19 surge in NYC commenced Kv3 modulator 3 in March and subsided by the finish of Might 2020 mainly. Many HCW data reported to day usually do not reveal the problem at the ultimate end from the surge, and could underestimate accurate seroprevalence. We explain SARS-CoV-2 seroprevalence in HCWs in a big inner-city medical center in NYC, june 26 with antibody tests carried out from Might 18 to, 2020, in the subsidence from the surge. To help expand our knowledge of occupational risk among different sets of HCWs, we examined associations of seroprevalence with HCWs work function and Kv3 modulator 3 function location. Strategies This is a cross-sectional seroprevalence research carried out in the BronxCare Wellness Program situated in Central and South Bronx, an particular area that experienced among the highest incidences of SARS-CoV-2 infections within NYCs five boroughs. June 26 HCWs had been provided voluntary tests for serum antibodies to SARS-CoV-2 between Might 18 and, 2020. Testing happened in the organizations auditorium, a central and accessible location easily. Regular email messages had been delivered to all division and workers mind through the tests period, giving antibody tests and offering tests and area period information. The Elecsys Anti-SARS-CoV-2 (Roche) assay calculating total qualitative antibodies was utilized; the assay includes a reported level of sensitivity of 97.1% 2 weeks after an optimistic SARS-CoV-2 RNA polymerase string reaction (PCR).